Free Newsletter
Biogen-Icahn showdown goes to a vote
Free newsletter via e-mail
Tools
Biogen Idec's proxy fight nears its culmination. Shareholders meet today to vote on a slate of directors named by activist investor Carl Icahn, who has called on the board to consider splitting the biotech giant in two. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: